Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 43

Sort by

Sort Order Select

Journal Articles

In This Issue of Diabetes

Max Bingham, PhD

Diabetes 2023;72(9):1177–1178

https://doi.org/10.2337/db23-ti09

Published: 21 August 2023

View article titled, In This Issue of <em>Diabetes</em>

Journal Articles

Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes

Saori Sako, Yumie Takeshita, Hiroaki Takayama, Hisanori Goto, Yujiro Nakano, Hitoshi Ando, Hiromasa Tsujiguchi, Tatsuya Yamashita, Kuniaki Arai, Shuichi Kaneko, Hiroyuki Nakamura, Kenichi Harada, Masao Honda, Toshinari Takamura

Diabetes 2023;72(9):1297–1306

https://doi.org/10.2337/db22-0933

Published: 21 June 2023

View article titled, Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes

Meeting Abstracts

95-OR: A New Composite Blood Biomarker Performs Well in the Diagnosis of NASH, Advanced Hepatic Fibrosis, and High-Risk NASH

DAE HO LEE

Diabetes 2023;72(Supplement_1):95-OR

https://doi.org/10.2337/db23-95-OR

Published: 20 June 2023

View article titled, 95-OR: A New Composite Blood Biomarker Performs Well in the Diagnosis of NASH, Advanced Hepatic Fibrosis, and High-Risk NASH

Meeting Abstracts

1582-P: Association of Low eGFR with Novel Liver Fibrosis Biomarker Mac-2 Binding Protein Glycosylation Isomer in Type 2 Diabetes Patients

EIICHIRO SUZUKI, YUMI SHINYA, BUNPEI KANARI, MISA KAMBARA, HIDEO TAKAHASHI

Diabetes 2023;72(Supplement_1):1582-P

https://doi.org/10.2337/db23-1582-P

Published: 20 June 2023

View article titled, 1582-P: Association of Low eGFR with Novel Liver Fibrosis Biomarker Mac-2 Binding Protein Glycosylation Isomer in Type 2 Diabetes Patients

Meeting Abstracts

1284-P: Prediabetes with Obesity Is a Major Risk Factor for NAFLD and Liver Fibrosis

EDDISON GODINEZ LEIVA, ROMINA LOMONACO, SULAV SHRESTHA, STEPHEN A. MARANGI, XIAOFEI CHI, SRILAXMI KALAVALAPALLI, SHWETHA S. SHETTY, ANDREA ORTIZ ROCHA, ENRIQUE VALDEZ SAENZ, MARIA A. GONZALEZ, LYDIA MANSOUR, MARIANNA M. CALVET, DIANA BARB, APRIL MATHEWS, ANU SHARMA, KENNETH CUSI

Diabetes 2023;72(Supplement_1):1284-P

https://doi.org/10.2337/db23-1284-P

Published: 20 June 2023

View article titled, 1284-P: Prediabetes with Obesity Is a Major Risk Factor for NAFLD and Liver Fibrosis

Meeting Abstracts

1606-P: Tg/HDL Ratio and Liver Fibrosis in Diabetic Patients at an Indian Tertiary Care Center

ABHISHEK CHANDRA, JYOTI DINKAR, RAJEEV RANJAN

Diabetes 2023;72(Supplement_1):1606-P

https://doi.org/10.2337/db23-1606-P

Published: 20 June 2023

View article titled, 1606-P: Tg/HDL Ratio and Liver Fibrosis in Diabetic Patients at an Indian Tertiary Care Center

Meeting Abstracts

1321-P: Screening for Liver Fibrosis in Diabetes—Assessing the Performance of Current Recommendations in a Large Unselected Population

FERNANDO BRIL, MEAGAN GRAY

Diabetes 2023;72(Supplement_1):1321-P

https://doi.org/10.2337/db23-1321-P

Published: 20 June 2023

View article titled, 1321-P: Screening for Liver Fibrosis in Diabetes—Assessing the Performance of Current Recommendations in a Large Unselected Population

Meeting Abstracts

1261-P: Prevalence of Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 1 Diabetes

TAREQ SALAH, SHAHEEN TOMAH, MARWA AL-BADRI, KARIM KIBAA, SHILTON E. DHAVER, MICHAEL P. CURRY, MICHELLE LAI, ZHENGHUI JIANG, ABDELRAHMAN KHATER, RYAN MCCARRAGHER, LILY DEMATTOS, MINH TRAN, OSAMA HAMDY

Diabetes 2023;72(Supplement_1):1261-P

https://doi.org/10.2337/db23-1261-P

Published: 20 June 2023

View article titled, 1261-P: Prevalence of Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 1 Diabetes

Meeting Abstracts

1313-P: The Prevalences of NAFLD and Liver Fibrosis Are High in Individuals with Type 1 Diabetes and Increase with Disease Progression

COCO FUHRI SNETHAGE, ABRAHAM S. MEIJNIKMAN, PLEUN DE GROEN, CENGIZ CALLENDER, ELENA RAMPANELLI, CATHERINE B. BROUWER, DANIËL VAN RAALTE, MAX NIEUWDORP, NORDIN HANSSEN

Diabetes 2023;72(Supplement_1):1313-P

https://doi.org/10.2337/db23-1313-P

Published: 20 June 2023

View article titled, 1313-P: The Prevalences of NAFLD and Liver Fibrosis Are High in Individuals with Type 1 Diabetes and Increase with Disease Progression

Meeting Abstracts

1347-P: Utility of Fibrosis-4 (FIB-4) and Nonalcoholic Fatty Liver Disease Fibrosis Scores (NFS) for Liver Fibrosis Screening in Asian-Indians with Type 2 Diabetes—A Cross-Sectional Observational Study

K. V RAVI TEJA, SHIVANI CHANDEL

Diabetes 2023;72(Supplement_1):1347-P

https://doi.org/10.2337/db23-1347-P

Published: 20 June 2023

View article titled, 1347-P: Utility of Fibrosis-4 (FIB-4) and Nonalcoholic Fatty Liver Disease Fibrosis Scores (NFS) for Liver Fibrosis Screening in Asian-Indians with Type 2 Diabetes—A Cross-Sectional Observational Study

Meeting Abstracts

1292-P: Serum Thrombospondin-2 Level as a Novel Liver Fibrosis Biomarker That Changes with Liver Stiffness Improvement in Patients with Type 2 Diabetes

JIMMY H.C. MAK, HO YI CAROL FONG, YING WONG, KATHRYN C. TAN, SIU LING KAREN LAM, CHI-HO LEE

Diabetes 2023;72(Supplement_1):1292-P

https://doi.org/10.2337/db23-1292-P

Published: 20 June 2023

View article titled, 1292-P: Serum Thrombospondin-2 Level as a Novel Liver Fibrosis Biomarker That Changes with Liver Stiffness Improvement in Patients with Type 2 Diabetes

Meeting Abstracts

96-OR: Liver Fibrosis Scores in Novel Subclusters of Patients at Risk for Type 2 Diabetes

VITORIA MINELLI FAIAO, ARVID SANDFORTH, SARAH KATZENSTEIN, ANDREAS FRITSCHE, LOUISE FRITSCHE, JÜRGEN MACHANN, FRITZ SCHICK, HANS-ULRICH HÄRING, ROBERT WAGNER, ANDREAS PETER, ANDREAS L. BIRKENFELD, NORBERT STEFAN, REINER JUMPERTZ VON SCHWARTZENBERG

Diabetes 2023;72(Supplement_1):96-OR

https://doi.org/10.2337/db23-96-OR

Published: 20 June 2023

View article titled, 96-OR: Liver Fibrosis Scores in Novel Subclusters of Patients at Risk for Type 2 Diabetes

Meeting Abstracts

98-OR: Oral Insulin Alleviates Liver Fibrosis and Reduces Fat in Patients with NASH and Type 2 Diabetes—Results of Phase II Clinical Trial

YUVAL ISHAY, JOEL M. NEUTEL, YOTAM KOLBEN, RAM GELMAN, ORLY SNEH ARBIB, OLIVER LOPEZ, ROBERTO SOTOLONGO, YARON ILAN, MIRIAM KIDRON

Diabetes 2023;72(Supplement_1):98-OR

https://doi.org/10.2337/db23-98-OR

Published: 20 June 2023

View article titled, 98-OR: Oral Insulin Alleviates Liver Fibrosis and Reduces Fat in Patients with NASH and Type 2 Diabetes—Results of Phase II Clinical Trial

Meeting Abstracts

119-LB: Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

JOHN B. PRINS, HARESSH SAJIIR, SAHAR KESHVARI, KUAN YAU WONG, JACK LOCKETT, MICHAEL MCGUCKIN, SUMAIRA Z. HASNAIN

Diabetes 2022;71(Supplement_1):119-LB

https://doi.org/10.2337/db22-119-LB

Published: 01 June 2022

View article titled, 119-LB: Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

Meeting Abstracts

1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia

APRIL MATHEWS, SRILAXMI KALAVALAPALLI, EDDISON GODINEZ, ROMINA LOMONACO, RACHEL E. DILLARD, MARIA A. GONZALEZ, STEPHEN A. MARANGI, SHWETHA S. SHETTY, SULAV SHRESTHA, LYDIA MANSOUR, MARGERY A. CONNELLY, KELLY Y. CHUN, DIANA BARB, KENNETH CUSI

Diabetes 2022;71(Supplement_1):1346-P

https://doi.org/10.2337/db22-1346-P

Published: 01 June 2022

View article titled, 1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia

Meeting Abstracts

1334-P: Hepatocyte D-ß-Hydroxybutyrate Dehydrogenase Deficiency Improves Glucose Homeostasis and Prevents Diet-Induced Liver Fibrosis

DAVID B. STAGG, ALISHA R. SEAY, ALISA B. NELSON, DANA ANDRE A. D’AVIGNON, CURTIS C. HUGHEY, PATRYCJA PUCHALSKA, PETER A. CRAWFORD

Diabetes 2022;71(Supplement_1):1334-P

https://doi.org/10.2337/db22-1334-P

Published: 01 June 2022

View article titled, 1334-P: Hepatocyte D-ß-Hydroxybutyrate Dehydrogenase Deficiency Improves Glucose Homeostasis and Prevents Diet-Induced Liver Fibrosis

Meeting Abstracts

480-P: Correlation of Tg/HDL Ratio and Liver Fibrosis in People with Diabetes in a Tertiary Care Center in India

AJOY TEWARI, VINEETA TEWARI, JAY TEWARI, BHARAT SABOO, ABHISHEK SHRIVASTAVA, S S. DARIYA, VIPUL CHAVDA, DHRUVI HASNANI, ANIKET V. INAMDAR, RUPAM CHOUDHURY

Diabetes 2022;71(Supplement_1):480-P

https://doi.org/10.2337/db22-480-P

Published: 01 June 2022

View article titled, 480-P: Correlation of Tg/HDL Ratio and Liver Fibrosis in People with Diabetes in a Tertiary Care Center in India

Meeting Abstracts

1105-P: Moderate-to-Advanced Liver Fibrosis Is Common in Patients with Type 1 Diabetes (T1D) and Nonalcoholic Fatty Liver Disease (NAFLD)

SHAHEEN TOMAH, TAREQ SALAH, MARWA AL-BADRI, SHILTON E. DHAVER, MICHAEL P. CURRY, ZHENGHUI JIANG, MICHELLE LAI, OMNIA A. ELENANI, KARIM KIBAA, HANNAH GARDNER, RYAN MCCARRAGHER, AARYA A. KAUSHIK, NOLAN A. ZIEMNIAK, OSAMA HAMDY

Diabetes 2022;71(Supplement_1):1105-P

https://doi.org/10.2337/db22-1105-P

Published: 01 June 2022

View article titled, 1105-P: Moderate-to-Advanced Liver Fibrosis Is Common in Patients with Type 1 Diabetes (T1D) and Nonalcoholic Fatty Liver Disease (NAFLD)

Meeting Abstracts

999-P: A Study to Assess Occurrence of NAFLD and Liver Fibrosis in Patients with T2DM and Associated Factors

C.L. NAWAL, ABHISHEK YADAV, PANKAJ MANGAL, ARADHANA SINGH

Diabetes 2021;70(Supplement_1):999-P

https://doi.org/10.2337/db21-999-P

Published: 01 June 2021

View article titled, 999-P: A Study to Assess Occurrence of NAFLD and Liver Fibrosis in Patients with T2DM and Associated Factors

Meeting Abstracts

211-LB: Antifibrotic Effect of a Novel Long-Acting GLP-1/GCG/FGF21/Anti-Cytokine Tetra-Specific Liver Microenvironment-Targeting Drug (OGB21502) in CCl4-Induced Liver Fibrosis Mice Model

MIN SUN KIM

Diabetes 2021;70(Supplement_1):211-LB

https://doi.org/10.2337/db21-211-LB

Published: 01 June 2021

View article titled, 211-LB: Antifibrotic Effect of a Novel Long-Acting GLP-1/GCG/FGF21/Anti-Cytokine Tetra-Specific Liver Microenvironment-Targeting Drug (OGB21502) in CCl4-Induced Liver Fibrosis Mice Model

NARROW

In This Issue of Diabetes

Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes

95-OR: A New Composite Blood Biomarker Performs Well in the Diagnosis of NASH, Advanced Hepatic Fibrosis, and High-Risk NASH

1582-P: Association of Low eGFR with Novel Liver Fibrosis Biomarker Mac-2 Binding Protein Glycosylation Isomer in Type 2 Diabetes Patients

1284-P: Prediabetes with Obesity Is a Major Risk Factor for NAFLD and Liver Fibrosis

1606-P: Tg/HDL Ratio and Liver Fibrosis in Diabetic Patients at an Indian Tertiary Care Center

1321-P: Screening for Liver Fibrosis in Diabetes—Assessing the Performance of Current Recommendations in a Large Unselected Population

1261-P: Prevalence of Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 1 Diabetes

1313-P: The Prevalences of NAFLD and Liver Fibrosis Are High in Individuals with Type 1 Diabetes and Increase with Disease Progression

1347-P: Utility of Fibrosis-4 (FIB-4) and Nonalcoholic Fatty Liver Disease Fibrosis Scores (NFS) for Liver Fibrosis Screening in Asian-Indians with Type 2 Diabetes—A Cross-Sectional Observational Study

1292-P: Serum Thrombospondin-2 Level as a Novel Liver Fibrosis Biomarker That Changes with Liver Stiffness Improvement in Patients with Type 2 Diabetes

96-OR: Liver Fibrosis Scores in Novel Subclusters of Patients at Risk for Type 2 Diabetes

98-OR: Oral Insulin Alleviates Liver Fibrosis and Reduces Fat in Patients with NASH and Type 2 Diabetes—Results of Phase II Clinical Trial

119-LB: Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease

1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia

1334-P: Hepatocyte D-ß-Hydroxybutyrate Dehydrogenase Deficiency Improves Glucose Homeostasis and Prevents Diet-Induced Liver Fibrosis

480-P: Correlation of Tg/HDL Ratio and Liver Fibrosis in People with Diabetes in a Tertiary Care Center in India

1105-P: Moderate-to-Advanced Liver Fibrosis Is Common in Patients with Type 1 Diabetes (T1D) and Nonalcoholic Fatty Liver Disease (NAFLD)

999-P: A Study to Assess Occurrence of NAFLD and Liver Fibrosis in Patients with T2DM and Associated Factors

211-LB: Antifibrotic Effect of a Novel Long-Acting GLP-1/GCG/FGF21/Anti-Cytokine Tetra-Specific Liver Microenvironment-Targeting Drug (OGB21502) in CCl4-Induced Liver Fibrosis Mice Model

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only